About: Bio-Israel

Vaxil Bio Ltd. (TASE: VAXL:IT) has recruited three additional patients, for its follow up clinical trial study (VAXIL-002) in patients with Multiple Myeloma at Hadassah Medical Center in Jerusalem. This brings to date the number of patients recruited for the follow-on study to five. The VAXIL-002 trial is a follow-up...

NanoPass Technologies has entered into a license agreement for its MicronJet delivery device with Janssen Pharmaceuticals for multiple vaccine fields. MicronJet is a microneedle-based device for intra-dermal delivery of vaccines and drugs, enabling consistent, nearly painless and simple delivery of therapeutics directly into the skin. MicronJet has proven efficacy and...

CollPlant (TASE:CLPT) has received CE mark approval for European sale and marketing of its Vergenix®WD product, a company-developed wound healing product. Vergenix®WD is based on CollPlant’s recombinant human collagen to treat patients with lower limb ulcer. Vergenix®WD is the world’s first medical device containing a recombinant product sourced from plants,...

BrainStorm Cell Therapeutics (OTC.QB: BCLI) has signed an agreement with Octane Biotech of Kingston, Ontario, to jointly develop a proprietary bioreactor for production of its NurOwn stem cell therapy candidate. The customized bioreactor will enable BrainStorm to optimize its NurOwn production process, significantly increasing its production capabilities by using a...